Timothya Yap News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer

Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomRadiopharm theranosticsInstitut gustave roussyTimothya yapEli lillyClinical developmentCancer research united kingdomUniversity of texas md anderson cancer centerTranslational researchBaptist health systemsBreast cancer congressBristol myers squibbKhalifa institute for personalized cancer therapyInstitute for applied cancer scienceTherapeutics discovery division

Next-generation PARP inhibitor shows clinical benefit in certain patients with breast cancer

Next-generation PARP inhibitor shows clinical benefit in certain patients with breast cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSaruparib astrazenecaBymatthew shinkleMindy valcarcelTimothya yapUniversity of texas md anderson cancer centerAmerican association for cancer research annual meetingAmerican associationCancer research annualCancer research annual meetingCancer centerPublished april

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients

Next-Gen PARP Inhibitor Shows Benefit in Breast Cancer Patients
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUnited kingdomHaihe biopharmaBiocity biopharmaCalithera biosciencesTerremoto biosciencesBridgene biosciencesEli lillyTimothya yapRadiopharm theranosticsArtios pharmaDaiichi sankyoInstitut gustave roussyAduro biotech incAtrin pharmaceuticals

Saruparib Generates Early Efficacy and Safety Signals in HRR-Mutant Advanced Breast Cancer

Saruparib's favorable activity and safety may allow patients with advanced solid tumors to stay on treatment longer vs other approved PARP inhibitors.

United statesTimothya yapUniversity of texas md anderson cancer centerInvestigational cancer therapeuticsCancer medicineCancer centerBreast cancerHrr mutations

2023-10-24 | NDAQ:APRE | Press Release | Aprea Therapeutics Inc

(2023-10-24 | NDAQ:APRE) Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways

United kingdomCity ofUnited statesUniversity of pennsylvaniaAprea closecurlyquoteFiona simpkinsYap closecurlyquoteAprea closecurlydoublequoteTimothy yapMike moyerTimothya yapSecurities exchangeCleveland clinic foundationJohns hopkins universityTranslational researchExchange commission